CEO " THE FDA Has Signaled OPENNESS and WILLINGNESS for Fast Approval. LINK
QUOTE FROM CEO ON AA :
Seeking Alpha 1/10/13
But most importantly we are achieving alignment with all the stakeholders in the DMD community, so we’ve been working with patient advocates with investigators who are experts in Duchenne, and we believe the FDA has really signaled in several ways their openness and willingness to consider accelerated approvaland for other expedited paths to approval for these types of devastating illnesses and including in the rare disease space.